Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aruto Sugiyama"'
Autor:
Aruto Sugiyama, Mitsuo Umetsu, Hikaru Nakazawa, Teppei Niide, Tomoko Onodera, Katsuhiro Hosokawa, Shuhei Hattori, Ryutaro Asano, Izumi Kumagai
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Small bispecific antibodies that induce T-cell–mediated cytotoxicity have the potential to damage late-stage tumor masses to a clinically relevant degree, but their cytotoxicity is critically dependent on their structural and functional pr
Externí odkaz:
https://doaj.org/article/f18cb9ec074743a0b52efdd168550715
Autor:
Yutaka Tamaru, Shuji Nakanishi, Kenya Tanaka, Mitsuo Umetsu, Hikaru Nakazawa, Aruto Sugiyama, Tomoyuki Ito, Naofumi Shimokawa, Masahiro Takagi
Publikováno v:
Journal of Bioscience and Bioengineering.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0df1d375139d52a0961cb923329d89be
https://doi.org/10.1016/j.jbiosc.2023.03.012
https://doi.org/10.1016/j.jbiosc.2023.03.012
Autor:
Mitsuo Umetsu, Tomoko Onodera-Sugano, Ryutaro Asano, Yoshikazu Tanaka, Izumi Kumagai, Hikaru Nakazawa, Aruto Sugiyama, Teppei Niide, Takamitsu Hattori, Hiromi Ogata
Publikováno v:
Biochemical Engineering Journal. 160:107636
Diabody 31, a bispecific therapeutic antibody, is a heterodimer comprised of two types of chimeric single-chain variable fragments (scFv), that has been identified as a clone with high cytotoxicity against cancer cells. Diabody 31 is inactive as a ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7006485e6351c2131f4fb1f8717a894
https://doi.org/10.1016/j.bej.2020.107636
https://doi.org/10.1016/j.bej.2020.107636
Autor:
Ryutaro Asano, Aruto Sugiyama, Teppei Niide, Takamitsu Hattori, Hikaru Nakazawa, Izumi Kumagai, Mitsuo Umetsu
Publikováno v:
Journal of bioscience and bioengineering. 126(2)
The cytotoxicity of T cell-recruiting antibodies with their potential to damage late-stage tumor masses is critically dependent on their structural and functional properties. Recently, we reported a semi-high-throughput process for screening highly c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d5d625f8df78462a4eb9461de540f79
https://pubmed.ncbi.nlm.nih.gov/29548844
https://pubmed.ncbi.nlm.nih.gov/29548844
Autor:
Tomoko Onodera, Katsuhiro Hosokawa, Mitsuo Umetsu, Aruto Sugiyama, Hikaru Nakazawa, Izumi Kumagai, Shuhei Hattori, Ryutaro Asano, Teppei Niide
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Small bispecific antibodies that induce T-cell–mediated cytotoxicity have the potential to damage late-stage tumor masses to a clinically relevant degree, but their cytotoxicity is critically dependent on their structural and functional properties.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da97faba65ac68d8bcad50105748f8aa
http://europepmc.org/articles/PMC5460266
http://europepmc.org/articles/PMC5460266
Autor:
Yuki, Shibuya, Natsuki, Haga, Ryutaro, Asano, Hikaru, Nakazawa, Takamitsu, Hattori, Daisuke, Takeda, Aruto, Sugiyama, Reiko, Kurotani, Izumi, Kumagai, Mitsuo, Umetsu, Koki, Makabe
Publikováno v:
Protein engineering, designselection : PEDS. 30(1)
Production of various combinations of bispecific variable domain of heavy chain of heavy chain-only antibody (VHH) constructs to evaluate their therapeutic potential usually requires several gene-engineering steps. Here, we present an alternative met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b027d49be9f6527f3b713ecdb18fdc0c
https://pubmed.ncbi.nlm.nih.gov/27881685
https://pubmed.ncbi.nlm.nih.gov/27881685
Autor:
Aruto Sugiyama, Izumi Kumagai, Koki Makabe, Yuki Shibuya, Reiko Kurotani, Natsuki Haga, Mitsuo Umetsu, Ryutaro Asano, Takamitsu Hattori, Hikaru Nakazawa, Daisuke Takeda
Publikováno v:
Protein Engineering, Design & Selection.
Production of various combinations of bispecific variable domain of heavy chain of heavy chain-only antibody (VHH) constructs to evaluate their therapeutic potential usually requires several gene-engineering steps. Here, we present an alternative met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::024d7f01a73e297f7a61041cf1070ca0
https://doi.org/10.1093/protein/gzw057
https://doi.org/10.1093/protein/gzw057
Autor:
Ryutaro Asano, Nobutaka Shimizu, Katsuhiro Hosokawa, Takuma Sujino, Mitsuo Umetsu, Hiroto Fujii, Takamitsu Hattori, Aruto Sugiyama, Izumi Kumagai, Yoshikazu Tanaka, Akira Shinoda, Tomoyuki Ito, Teppei Niide, Noriyoshi Manabe, Hikaru Nakazawa
Publikováno v:
Advanced Therapeutics. 1:1700031
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1e558529430626864dcf3de2ab77515
https://doi.org/10.1002/adtp.201700031
https://doi.org/10.1002/adtp.201700031
Autor:
Yuki Shibuya, Natsuki Haga, Ryutaro Asano, Hikaru Nakazawa, Takamitsu Hattori, Daisuke Takeda, Aruto Sugiyama, Reiko Kurotani, Izumi Kumagai, Mitsuo Umetsu, Koki Makabe
Publikováno v:
PEDS: Protein Engineering, Design & Selection; Jan2017, Vol. 30 Issue 1, p15-21, 7p